Gilead buys Arcellx for US$ 7.8 billion; FDA approves Vanda’s antipsychotic pill for bipolar disorder, schizophrenia
In this week’s news, Gilead Sciences has entered into an agreement to acquire its cancer therapy partner Arcellx for US$ ...
Impressions : 957
Lilly expects 25% growth, Novo sees its sales drop in 2026; Amgen turns down FDA request to withdraw rare disease drug
In this week’s Phispers, we bring you the split story of two GLP-1 drugmakers — Eli Lilly and Novo Nordisk. While L...
Impressions : 2891
Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US
In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...
Impressions : 1343
RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials
This week, US Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr. dismissed all 17 members of the US Centers for D...
Impressions : 1571
Roche buys rights to Zealand’s obesity med in US$ 5.3 bn deal; Merck wins Gardasil lawsuit, bolsters vaccine manufacturing
In news this week, Roche has acquired rights to develop and commercialize Zealand Pharma’s experimental obesity drug petr...
Impressions : 1511
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.